Humanized antibodies that recognize beta amyloid peptide

Abstract

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies.

1 . An antibody comprising a sequence having at least 95% identity with the sequence given by SEQ ID NO: 71 and a sequence having at least 95% identity with the sequence given by SEQ ID NO: 72.  
     
     
         2 . A polynucleotide compound, comprising a sequence coding for either a sequence having at least 95% identity with SEQ ID NO: 71 or a sequence having at least 95% identity with SEQ ID NO: 72 of the antibody of  claim 1 .  
     
     
         3 . A cell that is capable of expressing the antibody of  claim 1 .  
     
     
         4 . A pharmaceutical composition, comprising the antibody of  claim 1  and a pharmaceutically acceptable excipient.  
     
     
         5 . A method for treating clinical or pre-clinical Alzheimer's disease or Down's syndrome in a human subject, comprising administering to the human subject an effective amount of the antibody of  claim 1 .  
     
     
         6 . An antibody comprising a light chain comprising a sequence having at least 95% identity with the sequence given by SEQ ID NO: 71 and a heavy chain comprising a sequence having at least 95% identity with the sequence given by SEQ ID NO: 72.  
     
     
         7 . A polynucleotide compound, comprising a sequence coding for either a sequence having at least 95% identity with SEQ ID NO: 71 or a sequence having at least 95% identity with SEQ ID NO: 72 of the antibody of  claim 6 .  
     
     
         8 . A cell that is capable of expressing the antibody of  claim 6 .  
     
     
         9 . A pharmaceutical composition, comprising the antibody of  claim 6  and a pharmaceutically acceptable carrier.  
     
     
         10 . A method for treating clinical or pre-clinical Alzheimer's disease or Down's syndrome in a human subject, comprising administering to the human subject an effective amount of the antibody of  claim 6 .  
     
     
         11 . The antibody of  claim 6  having a light chain which further comprises light chain constant region sequence from human IgG1 and a heavy chain which further comprises heavy chain constant region sequence from human IgG1.  
     
     
         12 . A polynucleotide compound, comprising a sequence coding either the light chain or heavy chain of the antibody of  claim 11 .  
     
     
         13 . A cell that is capable of expressing the antibody of  claim 11 .  
     
     
         14 . A pharmaceutical composition, comprising the antibody of  claim 11  and a pharmaceutically acceptable excipient.  
     
     
         15 . A method for treating clinical or pre-clinical Alzheimer's Disease or Down's syndrome in a human subject, comprising administering to the human subject an effective amount of the antibody of  claim 11 .  
     
     
         16 . An antibody fragment comprising a sequence having at least 95% identity with the sequence given by SEQ ID NO: 71 and comprising a sequence having at least 95% identity with the sequence given by SEQ ID NO: 72  
     
     
         17 . The antibody fragment of  claim 16 , which is an Fab or an F(ab′)2 fragment.  
     
     
         18 . The antibody fragment of  claim 16 , which is a single chain.  
     
     
         19 . A polynucleotide compound, comprising a sequence coding for either the sequence having at least 95% identity with SEQ ID NO: 71 or the sequence having at least 95% identity with SEQ ID NO: 72 of the antibody fragment of  claim 16 .  
     
     
         20 . A cell that is capable of expressing the antibody fragment of  claim 16 .  
     
     
         21 . A pharmaceutical composition, comprising the antibody fragment of  claim 16  and a pharmaceutically acceptable excipient.  
     
     
         22 . A method for treating clinical or pre-clinical Alzheimer's disease or Down's syndrome in a human subject, comprising administering to the human subject an effective amount of the antibody fragment of  claim 16.